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The limited substantial therapeutic progresses observed in
the treatment of solid tumors require concerted efforts to
combine our thorough knowledge of the tumor biology with
a broader comprehension of themainmechanisms regulating
antitumor immune responses. In this context, in the last
decade, in parallel to the changeless therapeutic quest for tar-
geting molecules responsible for tumor progression, we have
witnessed a growing consensus on the potential strong effi-
cacy of combined immunotherapeutic approaches. Recently,
these strategies, which include cancer vaccine developments,
strenuously pursued for many years, have mainly focused
on breaking critical inhibitory immune checkpoint pathways
(i.e., PD1/PD-Ls axes), which limit the tumor aggression
by different immune cells including natural killer (NK)
and T lymphocytes. The strengthening of such endogenous
cytolytic effectors, complemented by favoring theirmigration
toward tumors, and/or the infusion of cells engineered with
improved function (i.e., with chimeric antigen receptors) is
widely considered in additional therapeutic protocols aimed
at obtaining a more durable tumor growth control. This goal
may also relate to the type of the hematopoietic stem cell
transplantation (HSCT) utilized, if included in the treatment
of the malignancy.
The papers featured in this issue provide useful informa-
tion for these rapidly moving above-mentioned fields. Some
of them describe new possiblemechanisms promoting tumor
resistance to effector cell- (like NK cells) mediated aggres-
sion or to chemotherapy in the tumor microenvironment
favoring tumor progression. Special interest is directed to
the possible role for peritumoral NK cells in shaping tumor
epithelialmesenchymal transition (EMT) and aggressiveness.
C. Goyvaerts and K. Breckpot provide here a useful and
comprehensive summary of the current knowledge on the
efficacy of vaccination strategies, which differ in the quality
of the dispensed antigens and adjuvants, in the modalities
of antigen delivery, and in the targeted dendritic cells (DC)
subtypes. J. Dannull and colleagues deepen the reasons
for the low immunogenicity of immunotherapy strategies
based on the infusion of DC-tumor hybrids alone, without
adjuvants, whereas another contribution by C. Sakalar and
coworkers shows the immunogenic potential of AMHR2
(anti-Müllerian hormone receptor II) molecule in murine
models. The efficacy of different vaccination strategies has
also been discussed by M. A. Huang and colleagues in the
context of pediatric cancer, especially in terms of antibody-
and cellular-based therapeutic approaches.These latest inter-
ventions include chimeric antigen receptor- (CAR-) T cell
based strategies, targeting different antigens in both solid
tumors and B cell leukemia. Along this line, B. Clémenceau
and colleagues show in vitro the efficacy of CAR-NK92 cells
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targeting the HER-2 antigen in breast cancer, but discourag-
ing in vivo activity in a NOD/SCID/IL-2Rg−/− mouse model,
due to an off-target effect of the CH2-CH3 hIgG2 spacer
of the CAR construct. By interacting with macrophages at
the edge of the tumor, the presence of the spacer in the
CAR blocked these engineered cells at the periphery of the
engrafted tumors, emphasizing critical issues for therapeutic
approaches based on engineered molecules and the need for
recruitment of effector cells in the tumor mass to obtain
clinical benefits. This last point has been also discussed by
C. Cantoni and coworkers who highlight the role of HMGB1
in amplifying the recruitment of NK cells towards tumor, in
addition to discussing HMGB1 as a promoter of tumor EMT.
HMGB1 also represents the focus of an interesting article
provided by V. Pistoia and A. Pezzolo who describe HMGB1
as a factor contributing to tumor resistance in antibody-based
immunotherapy. C. Cantoni and coworkers also discuss the
complexity of immunosuppressive mechanisms acting in the
tumor microenvironment and emphasize a possible role of
NK cells in exacerbating tumor aggressiveness from residual
cancer cells spared by NK cell mediated killing. This NK-
mediated protumoral effect may additionally be caused by
the induction/upregulation of ligands (i.e., PD-L1) involved
in immune checkpoints. Key immune checkpoints involved
in tumorigenesis, and more specifically in glioma genesis,
have been clearly discussed by E. S. Kim and colleagues
who also provide an overview of the existing preclinical
and clinical data, antitumor efficacy, and clinical appli-
cations for different checkpoints in glioma. Furthermore,
group summarizes results of therapies combining the above-
mentioned immunotherapeutic approaches with chemother-
apy and radiation. Along this line, a comprehensive review
is provided by J. Jacobs and colleagues, specifically focusing
their discussion on colorectal cancer.
Overall we have clear indications that the achievement
of a long-lasting efficacy in the treatment of cancer patients
cannot disregard the best combination of different thera-
peutic approaches, including HSCT, often planned in the
standard of care for different malignancies, such as high-
risk neuroblastoma or lymphoma. On this subject, R. Fedele
and colleagues provide an exhaustive discussion of the
clinical benefit of auto- and allo-HSCT options in relapsed
or refractory Hodgkin lymphoma, in parallel exploring
results derived from either standard or emerging treatment
strategies. Finally, the article provided by R. Ortenberg and
colleagues focuses onmelanoma and points out the relevance
of the timing of therapeutic interventions that may be guided
by evaluating appropriate serum tumor biomarkers. In this
context, the authors proposed the secreted form of CEA-
CAM1 as a useful tumor biomarker endowed with prognostic
role.
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